[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cornea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cornea":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,77,111,143,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639891","impact-of-glp-1-receptor-agonists-on-dry-eye-disease-in-patients-with-type-2-diabetes-mellitus-and-obesity-100639891",false,"NCT07605572","Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity","GALENOS","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs).\n3. Patients able to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients.\n2. History of multiple severe hypoglycemic episodes within the past two years.\n3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis.\n4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months.\n5. History of ketoacidosis or metabolic acidosis.\n6. History of corneal transplantation.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Diabetes mellitus (DM), prediabetes, and obesity are emerging as major global public health problems, with their epidemic spread continuously increasing over the past decades. The occurrence of diabetic retinopathy, cataract, glaucoma, and ocular surface disease in patients with diabetes mellitus has been extensively investigated in several studies. However, mild ocular surface disorders, such as dry eye disease, have often been overlooked, with a previous study showing that 51.3% of diabetes-related dry eye disease cases remained underdiagnosed. Among systemic diseases, diabetes mellitus and obesity have been associated with an increased risk of developing dry eye disease. Chronic hyperglycemia in diabetes leads to microvascular damage, including corneal neuropathy and reduced tear production, conditions that can disrupt ocular surface health, while systemic inflammation and meibomian gland dysfunction also contribute to this process. However, the effect of newer classes of antidiabetic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), on ocular surface health remains insufficiently understood. The aim of this prospective cohort study is to evaluate the effects of GLP-1 receptor agonists on dry eye disease in patients with type 2 diabetes mellitus and obesity through the assessment of ocular surface parameters, such as tear film break-up time, Schirmer test results, as well as potential changes in corneal topography.",[24,25,26,27,28,29],"Dry Eye Disease (DED)","Diabete Mellitus","GLP-1","Ocular Surface","Diabetes Type 2","Cornea",[31,28,32,29],"Dry eye disease","GLP-1 Receptor Agonists","RECRUITING","2026-05-29",{"date":36,"type":37},"2026-06-02","ACTUAL",{"date":39,"type":37},"2026-03-01",{"date":41,"type":20},"2027-02-28",{"name":43,"class":44},"Attikon Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100638628","acute-ocular-effects-of-cigarette-smoking-100638628","NCT07580040","Acute Ocular Effects of Cigarette Smoking","Acute Effects of Cigarette Smoking on Corneal Tomographic and Biometric Parameters: A Prospective Controlled Study","Inclusion Criteria:\n\n* Healthy adults aged 18 to 60 years\n* Current smokers in the smoking group\n* Never-smokers in the control group\n* Willing and able to undergo ophthalmic examination and Pentacam AXL measurements\n\nExclusion Criteria:\n\n* History of ocular surgery or ocular trauma\n* Presence of corneal disease, retinal disease, or ocular surface disorder\n* Clinically significant dry eye disease\n* Contact lens use within the last 2 weeks\n* Use of medications that may affect the ocular surface or pupillary dynamics, including anticholinergics or sympathomimetics\n* Systemic diseases such as diabetes mellitus or hypertension\n* Former smoking history in the control group\n* Use of electronic cigarettes or other tobacco products\n* Inability to cooperate adequately for accurate measurement",true,"60 Years",{"count":56,"type":20},90,"This prospective study aims to evaluate the short-term effects of smoking on corneal tomographic and biometric measurements in healthy adults. After baseline examinations and measurements are taken in both smoking and non-smoking participants, the same measurements will be repeated after 10 minutes of external exposure, and within-group and between-group changes will be compared. The aim of the study is to determine whether acute smoking exposure leads to measurable immediate changes in corneal tomographic and biometric parameters.",[59,29,60],"Smoking ( Cigarette)","Anterior Eye Segment Measurements",[62,63,64,65,66,67],"Cigarette Smoking","Corneal Tomography","Biometry","Pentacam","Anterior Segment","Corneal Densitometry","2026-05-05",{"date":70,"type":37},"2026-05-12",{"date":72,"type":37},"2026-02-15",{"date":74,"type":20},"2026-05",{"name":76,"class":44},"Istanbul University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":53,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100396242","fmri-and-ivcm-cornea-microscopy-of-cxl-in-keratoconus-100396242","NCT04439552","fMRI and IVCM Cornea Microscopy of CXL in Keratoconus","Neuroplasticity of Pain Pathways and Corneal Afferent Regeneration Following Corneal Crosslinking (CXL) in Keratoconus","Inclusion Criteria:\n\nCXL Group\n\n* Age 8-35 years\n* Clinical diagnosis of keratoconus and seeking CXL treatment\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nControl Group\n\n* Age 8-35 years\n* No diagnosis of keratoconus\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nExclusion Criteria (Both Groups):\n\n* Claustrophobic\n* Weight \\> 285 lbs (weight limit of the MRI table)\n* Significant medical history, including:\n\nCurrent DSM-IV-TR axis I psychiatric disorders. Chronic pain Significant head injury Seizures Brain tumor Cerebrovascular accident Neurological disease aside from migraine HIV-AIDs Prescription medication strongly implicated in causing dry eyes\n\n* Magnetic implants or metal-containing tattoos on their chest or above\n* Pregnancy\n* History of contact lens wear\n* Any allergic response to a numbing eyedrop in the past","8 Years","35 Years",{"count":87,"type":20},60,"Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).",[90,91,92,93,94,95,29,96],"Pain, Postoperative","Pain, Chronic","Pain, Acute","Surgical Injury","Surgical Wound","Cornea Injury","Keratoconus",[98,99,100,101],"fMRI","Corneal Microscopy","IVCM","Neuroimaging","2025-12-15",{"date":104,"type":37},"2025-12-19",{"date":106,"type":37},"2021-10-04",{"date":108,"type":20},"2027-12",{"name":110,"class":44},"Boston Children's Hospital",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":45},"100497633","oct-vibrography-for-biomechanical-properties-of-tissues-100497633","NCT05759780","OCT Vibrography for Biomechanical Properties of Tissues","A Study to Test the Potential of OCT Vibrography for Measuring Biomechanical Properties of Tissues","Group 1:\n\nInclusion criteria:\n\n• Subjects with healthy eyes (age 18 - 75, N = 50)\n\nExclusion criteria:\n\n* Subjects with history of eye diseases, and previous eye surgeries.\n* Subjects with diabetes, glaucoma family history\n* Subjects allergic to anesthetic eyedrop, especially proparacaine\n* Subjects with severe allergy\n* Subjects who have difficulty biting\n* Subjects who have recurrent corneal erosion\n\nGroup 2:\n\nInclusion criteria:\n\n• Subjects with healthy skin (age 18 - 75, N = 10)\n\nExclusion criteria:\n\n• Subjects with open cuts\u002Fsores on the skin, skin infection, or any contagious skin condition\n\nGroup 3:\n\nInclusion criteria:\n\n• Subjects with healthy gingiva (age 18 - 75, N = 10)\n\nExclusion criteria:\n\n• Subjects with open cuts\u002Fsores on the gingiva, gingiva infection, or any contagious gingiva condition\n\nGroup 4:\n\nInclusion criteria:\n\n• Mild or moderate keratoconus subjects (age 18 - 40, N = 20)\n\nExclusion criteria:\n\n• Subjects with K-max above 60 diopters (Pentacam imaging) are excluded","75 Years",{"count":56,"type":20},"INTERVENTIONAL",[122],"NA","The overall goal of this study is to develop OCT Vibrography (aka OCT elastography) as a novel tool for measuring biomechanical properties of human tissues in vivo.",[29,125,126],"Skin Diseases","Gingival Diseases",[128,129,130,131,132,133],"biomechanics","cornea","skin","gingiva","optical coherence tomography","vibrography","2025-10-21",{"date":136,"type":37},"2025-10-23",{"date":138,"type":37},"2023-08-19",{"date":140,"type":20},"2026-08-28",{"name":142,"class":44},"Massachusetts General Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":150,"targetDuration":4,"studyType":120,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100590106","intacs-for-non-ectatic-with-high-cylinder-100590106","NCT06963099","INTACS for Non Ectatic With High Cylinder","Use of Intra-corneal Ring Segments in Management of Non-ectatic Corneas With High Cylinder","Inclusion Criteria:\n\n* Non ectatic corneas with high cylinder error\n\nExclusion Criteria:\n\n* Corneal ectasia",{"count":151,"type":20},50,[122],"Intra-corneal rings implantation for correcting high cylinder errors in non ectatic corneas",[29],"2025-05-09",{"date":157,"type":37},"2025-05-14",{"date":159,"type":37},"2023-12-01",{"date":161,"type":20},"2025-07",{"name":163,"class":44},"Elshimaa A.Mateen",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":45},"100308762","accuracy-of-corneal-astigmatism-in-different-region-modes-100308762","NCT03299530","Accuracy of Corneal Astigmatism in Different Region Modes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.\n* Best corrected visual acuity ≥ 0.66 (20\u002F30 Snellen)\n\nExclusion Criteria:\n\n* Corneal diseases or severe irregular astigmatism (e.g., pterygium, keratoconus), existence of corneal opacification;\n* Ocular disease which may affect visual acuity (e.g., glaucoma, uveitis, retinal disease, pathologic myopia);\n* History of ocular surgery or ocular trauma before this cataract surgery;\n* Decentration of IOL \\> 0.3mm or tilt \\> 5°\n* Implantation of multifocal IOL\n* history of wearing of rigid contact lens within the past 4 weeks or soft contact lens within 1 week;",{"count":171,"type":20},70,"To analyze the difference between measured total corneal astigmatism and actual corneal astigmatism under different region modes and optimize the region setting.",[174,29],"Astigmatism",[176,177,178,179],"Corneal Astigmatism","Scheimpflug","pupil size","Toric","2024-07-22",{"date":182,"type":37},"2024-07-23",{"date":184,"type":37},"2017-10-10",{"date":186,"type":20},"2026-10-28",{"name":188,"class":44},"Wenzhou Medical University"]